Against this backdrop, the Leadership Summit will return to CPHI Milan in 2026, bringing senior pharmaceutical ...

AZ's $2 billion investment – at $18.36 per share – puts the UK-headquartered company in the driving seat to pair its ...

MSD has signed a global license agreement for a KRAS G12D inhibitor from China's SciBrunch Therapeutics, paying $400 million ...

A healthcare breakthrough may be supported by compelling evidence and formally recommended for use, but patients will only ...

The CRM system shows that the field rep called on schedule, delivered the primary brand message, and logged a positive interaction. What the call report fails to capture is that the regional sickness ...

Other candidates in its pipeline include injectable GIP/GLP-1 agonist enicepatide, injectable amylin analogue petrelintide, ...

Patients with fibrodysplasia ossificans progressiva (FOP) in the US will soon have the option of treatment with another daily ...

A team from the Garvan Institute of Medical Research in Darlinghurst, New South Wales, have used an emerging form of genetic ...

The first product from AbbVie's $8.7 billion takeover of Cerevel two years ago – Parkinson's disease therapy tavapadon – has ...

MSD and Daiichi Sankyo's regulatory efforts for their antibody-drug conjugates (ADCs) for cancer have stuttered again, with a ...

The off switch needs authority. The people carrying on after it is used need a budget. Editorial disclosure: The medicines ...

The Swiss pharma group has just reported topline results from the phase 3 IMAgINATION study of Factor B inhibitor sefaxersen ...